Study of a new bladder cancer drug for recurrent tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have recurrent non-muscle invasive bladder cancer (cancer that hasn't grown into the bladder muscle) that is either high-grade (more aggressive) or low-grade (less aggressive) and has come back after treatment.
- If your cancer is high-grade, you must have tried BCG treatment and it stopped working, or you couldn't tolerate it, or you have a small high-grade tumor that didn't respond to other therapy.
- If your cancer is low-grade, it must have come back within a year, or be larger than 3 cm, or have multiple tumors, or have grown slightly into the bladder lining (T1).
- You are generally healthy enough for daily activities (ECOG score 0-2) and have adequate organ function (kidneys, liver, blood counts).
- You haven't had certain previous treatments like other adenovirus-based therapies or immune modulators within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This study tests a new sustained-release chemotherapy (NDV-01) given directly into the bladder for people with non-muscle invasive bladder cancer that hasn't responded to BCG therapy or is at intermediate risk. It compares the new drug to standard chemotherapy to see if it can delay or prevent cancer from coming back.
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
This trial tests a new ablation therapy (a treatment that destroys tumors without surgery) in people with low-grade, non-invasive bladder cancer that comes back. It aims to see if this therapy can help avoid repeated surgeries.
This trial tests two new drugs (SHR-1501 and SHR-2005) given directly into the bladder for people with high-risk bladder cancer that can't be fully removed with standard surgery and who aren't able to have their bladder removed. The goal is to see if this combination can control the cancer and avoid the need for bladder removal.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.